ReviewResearch and practice in thrombosis and haemostasis2018
Novel aspects of antiplatelet therapy in cardiovascular disease.
Review in Research and practice in thrombosis and haemostasis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Chitosan-Based Scaffolds for the Treatment of Myocardial Infarction: A Systematic Review.Molecules (Basel, Switzerland) · 2023Pooled it
- Extended dual antiplatelet therapy with ticagrelor 60 mg in patients with prior myocardial infarction: The design of ALETHEIA, a multi-country observational study.Clinical cardiology · 2021Pooled it
- Clinical pharmacology of antiplatelet drugs: implications for personalized therapy.European journal of clinical pharmacology · 2026Review
- Sex-Related Differences in On-Treatment Platelet Reactivity in Patients with Acute Coronary Syndrome.Biomedicines · 2025Article
- Platelet Pathophysiology: Unexpected New Research Directions.Seminars in thrombosis and hemostasis · 2024Article
- Platelet reactivity is associated with pump thrombosis in patients with left ventricular assist devices.Research and practice in thrombosis and haemostasis · 2024Article
- Comparison of the effects of the GPIIb-IIIa antagonist Zalunfiban and the P2Y12 antagonist Selatogrel on Platelet Aggregation.Journal of thrombosis and thrombolysis · 2023Article
- Growth Differentiation Factor 15 Is Associated with Platelet Reactivity in Patients with Acute Coronary Syndrome.Journal of clinical medicine · 2023Article
- Protease-activated receptor-mediated platelet aggregation in patients with type 2 diabetes on potent P2YDiabetic medicine : a journal of the British Diabetic Association · 2022Article
- Growth Differentiation Factor-15 Correlates Inversely with Protease-Activated Receptor-1-Mediated Platelet Reactivity in Patients with Left Ventricular Assist Devices.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Platelet in thrombo-inflammation: Unraveling new therapeutic targets.Frontiers in immunology · 2022Review
- Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases.International journal of molecular sciences · 2021Review
- Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Coronary Syndrome: Implications for Platelet Reactivity?Cardiovascular drugs and therapy · 2021Article
- Regulation of Key Antiplatelet Pathways by Bioactive Compounds with Minimal Bleeding Risk.International journal of molecular sciences · 2021Review
- Characteristics and clinical outcomes of patients with acute gastrointestinal bleeding related to anticoagulant or antiplatelet therapy: a retrospective study.Croatian medical journal · 2021Article
- Effect of Prostanoids on Human Platelet Function: An Overview.International journal of molecular sciences · 2020Review
- Platelets in Healthy and Disease States: From Biomarkers Discovery to Drug Targets Identification by Proteomics.International journal of molecular sciences · 2020Review
- Ticagrelor Inhibits Toll-Like and Protease-Activated Receptor Mediated Platelet Activation in Acute Coronary Syndromes.Cardiovascular drugs and therapy · 2020Observational
- The dual role of platelet-innate immune cell interactions in thrombo-inflammation.Research and practice in thrombosis and haemostasis · 2020Review
- α-Hydroxybutyrate dehydrogenase is associated with atherothrombotic events following infrainguinal angioplasty and stenting.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiplatelet therapy is a cornerstone in the secondary prophylaxis of adverse cardiovascular events such as myocardial infarction and stroke. The cyclooxygenase inhibitor aspirin remains the most frequently prescribed antiplatelet drug, followed by adenosine diphosphate P2Y
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.